Deparment of Clinical Medicine, Universidade Federal Fluminense, Niterói, Rio de Janeiro, Brazil.
J Cardiovasc Pharmacol. 2020 Jul;76(1):42-49. doi: 10.1097/FJC.0000000000000839.
Anakinra is a recombinant human interleukin 1 receptor antagonist that competes and blocks the biologic effects of interleukin 1, reducing systemic inflammatory responses. In the 2015 guidelines for the diagnosis and management of pericardial diseases of the European Society of Cardiology, anakinra was established as a third-line therapy option for refractory recurrent pericarditis (RP). Recently, important studies that investigates the effect and safety of anakinra in RP were published, such as the AIRTRIP trial and the International Registry of Anakinra for Pericarditis. This article presents the current evidence about the effectiveness and safety of anakinra in RP and discusses its clinical application and mechanisms.
阿那白滞素是一种重组人白细胞介素 1 受体拮抗剂，可与白细胞介素 1 竞争并阻断其生物学效应，从而减少全身炎症反应。在 2015 年欧洲心脏病学会心包疾病诊断和管理指南中，阿那白滞素被确立为难治性复发性心包炎（RP）的三线治疗选择。最近，发表了一些重要的研究，探讨了阿那白滞素在 RP 中的疗效和安全性，如 AIRTRIP 试验和阿那白滞素治疗心包炎国际登记处。本文介绍了阿那白滞素治疗 RP 的有效性和安全性的现有证据，并讨论了其临床应用和作用机制。
